AR078321A1 - Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) - Google Patents
Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9)Info
- Publication number
- AR078321A1 AR078321A1 ARP100103239A ARP100103239A AR078321A1 AR 078321 A1 AR078321 A1 AR 078321A1 AR P100103239 A ARP100103239 A AR P100103239A AR P100103239 A ARP100103239 A AR P100103239A AR 078321 A1 AR078321 A1 AR 078321A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkyl
- haloalkyl
- hydrogen
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
También se proporciona un compuesto de la formula 1 para el tratamiento de una enfermedad o condicion mediada por un inhibidor de la cinasa dependiente de ciclina (CDK). Reivindicacion 1: Un compuesto de la formula 1 o una sal farmacéuticamente aceptable del mismo, en donde: R1 se selecciona a partir de -(CH2)0-2-heteroarilo, -(CH2)0-2-arilo, alquilo de 1 a 8 átomos de carbono, alquilo de 1 a 8 átomos de carbono ramificado, cicloalquilo de 1 a 8 átomos de carbono, y un grupo hetero-cicloalquilo de 4 a 8 miembros, en donde los grupos están cada uno opcionalmente sustituidos independientemente; R2 se selecciona a partir de hidrogeno, alcoxilo de 1 a 4 átomos de carbono, haloalquilo de 1 a 4 átomos de carbono, alquilo de 1 a 4 átomos de carbono, y halogeno; A1 es N; A4 es CR6; R4 se selecciona a partir de hidrogeno, halogeno, heterociclilo-R14 de 5 a 7 miembros, y A6-L-R9; R5 se selecciona a partir de hidrogeno, alquilo de 1 a 4 átomos de carbono, haloalquilo de 1 a 4 átomos de carbono, hidroxilo, CN, -O-alquilo de 1 a 4 átomos de carbono, -O-haloalquilo de 1 a 4 átomos de carbono, cicloalquilo de 3 a 4 átomos de carbono, halo-cicloalquilo de 3 a 4 átomos de carbono, y halogeno; R6 se selecciona a partir de hidrogeno, alquilo de 1 a 4 átomos de carbono, haloalquilo de 1 a 4 átomos de carbono, CN, -O- alquilo de 1 a 4 átomos de carbono, cicloalquilo de 3 a 4 átomos de carbono, halo-cicloalquilo de 3 a 4 átomos de carbono, -O-haloalquilo de 1 a 4 átomos de carbono, y halogeno; R7 se selecciona a partir de hidrogeno, alquilo de 1 a 4 átomos de carbono, haloalquilo de 1 a 4 átomos de carbono, O-alquilo de 1 a 3 átomos de carbono, y halogeno; A6 se selecciona a partir de O, SO2, y NR8; L se selecciona a partir de alquileno de 0 a 3 átomos de carbono, -CHD-, -CD2-, cicloalquilo de 3 a 6 átomos de carbono, halo-cicloalquilo de 3 a 6 átomos de carbono, hetero-cicloalquilo de 4 a 7 átomos de carbono, alquileno de 3 a 8 átomos de carbono ramificado, halo-alquileno de 3 a 8 átomos de carbono ramificado; R8 se selecciona a partir de hidrogeno, alquilo de 1 a 4 átomos de carbono, y alquilo de 3 a 8 átomos de carbono ramificado, y haloalquilo de 3 a 8 átomos de carbono ramificado; R9 se selecciona a partir de hidrogeno, alquilo de 1 a 6 átomos de carbono, cicloalquilo de 1 a 8 átomos de carbono, alquilo de 1 a 8 átomos de carbono ramificado, -(CH2)0-2-heteroarilo, (CH2)0-2-heterociclo-alquilo de 4 a 8 miembros, y (CH2)0-2-arilo, en donde los grupos están opcionalmente sustituidos; y R14 se selecciona a partir de hidrogeno, fenilo, halogeno, hidroxilo, alquilo de 1 a 4 átomos de carbono, alquilo de 3 a 6 átomos de carbono ramificado, haloalquilo de 1 a 4 átomos de carbono, CF3, =O, y O-alquilo de 1 a 4 átomos de carbono.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27593809P | 2009-09-04 | 2009-09-04 | |
| US28496109P | 2009-12-28 | 2009-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078321A1 true AR078321A1 (es) | 2011-11-02 |
Family
ID=43478200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103239A AR078321A1 (es) | 2009-09-04 | 2010-09-03 | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110130380A1 (es) |
| EP (1) | EP2473499A1 (es) |
| KR (1) | KR20120092586A (es) |
| CN (1) | CN102471310A (es) |
| AR (1) | AR078321A1 (es) |
| AU (1) | AU2010291206A1 (es) |
| CA (1) | CA2771563A1 (es) |
| MX (1) | MX2012002761A (es) |
| TW (1) | TW201113273A (es) |
| UY (1) | UY32877A (es) |
| WO (1) | WO2011026911A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| EP2668162A1 (en) * | 2011-01-28 | 2013-12-04 | Novartis AG | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| TN2016000270A1 (en) * | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CA3037456A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| EP3804724B1 (en) | 2016-10-20 | 2022-12-07 | Pfizer Inc. | Cdk inhibitors for treating pah |
| BR112019022511A2 (pt) | 2017-05-02 | 2020-05-12 | Novartis Ag | Terapia de combinação |
| US20230102081A1 (en) * | 2019-12-09 | 2023-03-30 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| CN115381824B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115448874B (zh) * | 2021-06-09 | 2024-11-01 | 石药集团中奇制药技术（石家庄）有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2005040152A1 (en) * | 2003-10-20 | 2005-05-06 | E.I. Dupont De Nemours And Company | Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides |
| EA200900799A1 (ru) * | 2006-12-22 | 2009-12-30 | Новартис Аг | Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями |
-
2010
- 2010-09-02 MX MX2012002761A patent/MX2012002761A/es not_active Application Discontinuation
- 2010-09-02 KR KR1020127008620A patent/KR20120092586A/ko not_active Application Discontinuation
- 2010-09-02 CA CA2771563A patent/CA2771563A1/en not_active Abandoned
- 2010-09-02 US US12/874,389 patent/US20110130380A1/en not_active Abandoned
- 2010-09-02 AU AU2010291206A patent/AU2010291206A1/en not_active Abandoned
- 2010-09-02 EP EP10750114A patent/EP2473499A1/en not_active Withdrawn
- 2010-09-02 WO PCT/EP2010/062893 patent/WO2011026911A1/en active Application Filing
- 2010-09-02 CN CN2010800367237A patent/CN102471310A/zh active Pending
- 2010-09-03 UY UY0001032877A patent/UY32877A/es not_active Application Discontinuation
- 2010-09-03 AR ARP100103239A patent/AR078321A1/es unknown
- 2010-09-03 TW TW099129948A patent/TW201113273A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120092586A (ko) | 2012-08-21 |
| EP2473499A1 (en) | 2012-07-11 |
| TW201113273A (en) | 2011-04-16 |
| WO2011026911A8 (en) | 2011-04-21 |
| UY32877A (es) | 2011-04-29 |
| WO2011026911A1 (en) | 2011-03-10 |
| MX2012002761A (es) | 2012-04-19 |
| CN102471310A (zh) | 2012-05-23 |
| US20110130380A1 (en) | 2011-06-02 |
| AU2010291206A1 (en) | 2012-02-23 |
| CA2771563A1 (en) | 2011-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078321A1 (es) | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) | |
| AR077505A1 (es) | Compuestos de piridina y sus usos | |
| AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
| AR079529A1 (es) | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR107633A1 (es) | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |